Sonja E. Steigen

TL;DR: Although the modified NIH classification is the best criteria to identify a single high-risk group for consideration of adjuvant therapy, the prognostic contour maps resulting from non-linear modelling are appropriate for estimation of individualised outcomes.

TL;DR: Evaluating the clinicopathologic profile of GISTs that have KIT exon 13 or exon 17 mutations found that Gastric KITExon 13 mutant GIST's tend to be slightly larger and more aggressive than gastric GIST’s in average, whereas the behavior of small intestinal Gists with KITexon 13 mutations does not differ from other small intestinalGISTs.

TL;DR: GISTs with an identical KIT orPDGFRA mutation may have widely varying risks for recurrence, and most of the patients with PDGFRA mutations and those with KIT exon 11 duplication mutation or deletion of one codon have favorable RFS with surgery alone and are usually not candidates for adjuvant therapy.

TL;DR: The great majority of GISTs with ITDs in the 3′ KIT-JM were mitotically inactive tumors occurring predominantly in the stomach and that seemed to have a favorable course, which suggests that presence of these IDTs may define a clinicopathologically favorable subset of Gists.

TL;DR: The molecular targets for therapeutic interventions are not only of importance for the treatment of GIST patients but also useful for in the development of novel drug modalities and new strategies in basic cancer therapy.